AbbVie | ABBV - Operating Expenses

Stock Price
228.45
Daily Change
3.64 1.62%
Monthly
3.48%
Yearly
11.94%
Q1 Forecast
217.84

AbbVie reported $10.81B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Abbott USD 9.21B 17M Dec/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
J&J USD 18.97B 2.38B Dec/2025
Medtronic USD 7.28B 16M Dec/2025
Merck USD 10.16B 558M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.36B 108M Dec/2024
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Zoetis USD 1.55B 3.85B Dec/2025